201 related articles for article (PubMed ID: 33734864)
1. Low-Dose Tamoxifen for Mammographic Density Reduction: A Randomized Controlled Trial.
Eriksson M; Eklund M; Borgquist S; Hellgren R; Margolin S; Thoren L; Rosendahl A; Lång K; Tapia J; Bäcklund M; Discacciati A; Crippa A; Gabrielson M; Hammarström M; Wengström Y; Czene K; Hall P
J Clin Oncol; 2021 Jun; 39(17):1899-1908. PubMed ID: 33734864
[TBL] [Abstract][Full Text] [Related]
2. RAZOR: A Phase II Open Randomized Trial of Screening Plus Goserelin and Raloxifene Versus Screening Alone in Premenopausal Women at Increased Risk of Breast Cancer.
Howell A; Ashcroft L; Fallowfield L; Eccles DM; Eeles RA; Ward A; Brentnall AR; Dowsett M; Cuzick JM; Greenhalgh R; Boggis C; Motion J; Sergeant JC; Adams J; Evans DG
Cancer Epidemiol Biomarkers Prev; 2018 Jan; 27(1):58-66. PubMed ID: 29097444
[No Abstract] [Full Text] [Related]
3. A Randomized Controlled Trial of Green Tea Extract Supplementation and Mammographic Density in Postmenopausal Women at Increased Risk of Breast Cancer.
Samavat H; Ursin G; Emory TH; Lee E; Wang R; Torkelson CJ; Dostal AM; Swenson K; Le CT; Yang CS; Yu MC; Yee D; Wu AH; Yuan JM; Kurzer MS
Cancer Prev Res (Phila); 2017 Dec; 10(12):710-718. PubMed ID: 28904061
[TBL] [Abstract][Full Text] [Related]
4. Use of Low-Dose Tamoxifen to Increase Mammographic Screening Sensitivity in Premenopausal Women.
Eriksson M; Czene K; Conant EF; Hall P
Cancers (Basel); 2021 Jan; 13(2):. PubMed ID: 33467653
[TBL] [Abstract][Full Text] [Related]
5. Prognostic effect of circulating adiponectin in a randomized 2 x 2 trial of low-dose tamoxifen and fenretinide in premenopausal women at risk for breast cancer.
Macis D; Gandini S; Guerrieri-Gonzaga A; Johansson H; Magni P; Ruscica M; Lazzeroni M; Serrano D; Cazzaniga M; Mora S; Feroce I; Pizzamiglio M; Sandri MT; Gulisano M; Bonanni B; Decensi A
J Clin Oncol; 2012 Jan; 30(2):151-7. PubMed ID: 22162577
[TBL] [Abstract][Full Text] [Related]
6. Baseline breast tissue characteristics determine the effect of tamoxifen on mammographic density change.
Gabrielson M; Hammarström M; Bergqvist J; Lång K; Rosendahl AH; Borgquist S; Hellgren R; Czene K; Hall P
Int J Cancer; 2024 Jul; 155(2):339-351. PubMed ID: 38554131
[TBL] [Abstract][Full Text] [Related]
7. Uptake of tamoxifen in consecutive premenopausal women under surveillance in a high-risk breast cancer clinic.
Donnelly LS; Evans DG; Wiseman J; Fox J; Greenhalgh R; Affen J; Juraskova I; Stavrinos P; Dawe S; Cuzick J; Howell A
Br J Cancer; 2014 Apr; 110(7):1681-7. PubMed ID: 24594998
[TBL] [Abstract][Full Text] [Related]
8. Mammographic screening and mammographic patterns.
Day N; Warren R
Breast Cancer Res; 2000; 2(4):247-51. PubMed ID: 11250716
[TBL] [Abstract][Full Text] [Related]
9. A randomized controlled trial of metformin in women with components of metabolic syndrome: intervention feasibility and effects on adiposity and breast density.
Tapia E; Villa-Guillen DE; Chalasani P; Centuori S; Roe DJ; Guillen-Rodriguez J; Huang C; Galons JP; Thomson CA; Altbach M; Trujillo J; Pinto L; Martinez JA; Algotar AM; Chow HS
Breast Cancer Res Treat; 2021 Nov; 190(1):69-78. PubMed ID: 34383179
[TBL] [Abstract][Full Text] [Related]
10. The Potential for Mammographic Breast Density Change as a Biosensor of Adjuvant Tamoxifen Therapy Adherence and Response.
Mullooly M; Gierach GL
JNCI Cancer Spectr; 2018 Nov; 2(4):pky072. PubMed ID: 30746510
[No Abstract] [Full Text] [Related]
11. Comparison of Radiation With or Without Concurrent Trastuzumab for HER2-Positive Ductal Carcinoma In Situ Resected by Lumpectomy: A Phase III Clinical Trial.
Cobleigh MA; Anderson SJ; Siziopikou KP; Arthur DW; Rabinovitch R; Julian TB; Parda DS; Seaward SA; Carter DL; Lyons JA; Dillmon MS; Magrinat GC; Kavadi VS; Zibelli AM; Tiriveedhi L; Hill ML; Melnik MK; Beriwal S; Mamounas EP; Wolmark N
J Clin Oncol; 2021 Jul; 39(21):2367-2374. PubMed ID: 33739848
[TBL] [Abstract][Full Text] [Related]
12. Mutations in
Fasching PA; Yadav S; Hu C; Wunderle M; Häberle L; Hart SN; Rübner M; Polley EC; Lee KY; Gnanaolivu RD; Hadji P; Hübner H; Tesch H; Ettl J; Overkamp F; Lux MP; Ekici AB; Volz B; Uhrig S; Lüftner D; Wallwiener M; Müller V; Belleville E; Untch M; Kolberg HC; Beckmann MW; Reis A; Hartmann A; Janni W; Wimberger P; Taran FA; Fehm TN; Wallwiener D; Brucker SY; Schneeweiss A; Hartkopf AD; Couch FJ
J Clin Oncol; 2021 May; 39(15):1619-1630. PubMed ID: 33780288
[TBL] [Abstract][Full Text] [Related]
13. Palbociclib for Residual High-Risk Invasive HR-Positive and HER2-Negative Early Breast Cancer-The Penelope-B Trial.
Loibl S; Marmé F; Martin M; Untch M; Bonnefoi H; Kim SB; Bear H; McCarthy N; Melé Olivé M; Gelmon K; García-Sáenz J; Kelly CM; Reimer T; Toi M; Rugo HS; Denkert C; Gnant M; Makris A; Koehler M; Huang-Bartelett C; Lechuga Frean MJ; Colleoni M; Werutsky G; Seiler S; Burchardi N; Nekljudova V; von Minckwitz G
J Clin Oncol; 2021 May; 39(14):1518-1530. PubMed ID: 33793299
[TBL] [Abstract][Full Text] [Related]
14. Correlative Biomarker Analysis of Intrinsic Subtypes and Efficacy Across the MONALEESA Phase III Studies.
Prat A; Chaudhury A; Solovieff N; Paré L; Martinez D; Chic N; Martínez-Sáez O; Brasó-Maristany F; Lteif A; Taran T; Babbar N; Su F
J Clin Oncol; 2021 May; 39(13):1458-1467. PubMed ID: 33769862
[TBL] [Abstract][Full Text] [Related]
15. Breast cancer.
Loibl S; Poortmans P; Morrow M; Denkert C; Curigliano G
Lancet; 2021 May; 397(10286):1750-1769. PubMed ID: 33812473
[TBL] [Abstract][Full Text] [Related]
16. Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial.
Poveda A; Floquet A; Ledermann JA; Asher R; Penson RT; Oza AM; Korach J; Huzarski T; Pignata S; Friedlander M; Baldoni A; Park-Simon TW; Tamura K; Sonke GS; Lisyanskaya A; Kim JH; Filho EA; Milenkova T; Lowe ES; Rowe P; Vergote I; Pujade-Lauraine E;
Lancet Oncol; 2021 May; 22(5):620-631. PubMed ID: 33743851
[TBL] [Abstract][Full Text] [Related]
17. Clinical Outcomes With Abemaciclib After Prior CDK4/6 Inhibitor Progression in Breast Cancer: A Multicenter Experience.
Wander SA; Han HS; Zangardi ML; Niemierko A; Mariotti V; Kim LSL; Xi J; Pandey A; Dunne S; Nasrazadani A; Kambadakone A; Stein C; Lloyd MR; Yuen M; Spring LM; Juric D; Kuter I; Sanidas I; Moy B; Mulvey T; Vidula N; Dyson NJ; Ellisen LW; Isakoff S; Wagle N; Brufsky A; Kalinsky K; Ma CX; O'Shaughnessy J; Bardia A
J Natl Compr Canc Netw; 2021 Mar; ():1-8. PubMed ID: 33761455
[TBL] [Abstract][Full Text] [Related]
18. Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer.
Kelly RJ; Ajani JA; Kuzdzal J; Zander T; Van Cutsem E; Piessen G; Mendez G; Feliciano J; Motoyama S; Lièvre A; Uronis H; Elimova E; Grootscholten C; Geboes K; Zafar S; Snow S; Ko AH; Feeney K; Schenker M; Kocon P; Zhang J; Zhu L; Lei M; Singh P; Kondo K; Cleary JM; Moehler M;
N Engl J Med; 2021 Apr; 384(13):1191-1203. PubMed ID: 33789008
[TBL] [Abstract][Full Text] [Related]
19. Impact of adjuvant endocrine therapy in older patients with comorbidities and estrogen receptor-positive, node-negative breast cancer-A National Cancer Database analysis.
Tamirisa N; Lin H; Shen Y; Shaitelman SF; Karuturi MS; Giordano SH; Babiera GV; Bedrosian I
Cancer; 2021 Jul; 127(13):2196-2203. PubMed ID: 33735487
[TBL] [Abstract][Full Text] [Related]
20. Body Mass Index and Risk of Second Cancer Among Women With Breast Cancer.
Feigelson HS; Bodelon C; Powers JD; Curtis RE; Buist DSM; Veiga LHS; Bowles EJA; Berrington de Gonzalez A; Gierach GL
J Natl Cancer Inst; 2021 Sep; 113(9):1156-1160. PubMed ID: 33823007
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
